P119: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1B CROSSWALK-A TRIAL EVALUATING THE SAFETY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)

• P Bartolucci,
• K Ataga,
• M Callaghan,
• L De Franceschi,
• C Minniti,
• A Alexandrou,
• D Imbs,
• R Fox,
• H Patel,
• A Sostelly,
• J Schimmel

Affiliations

P Bartolucci

1 University Paris-East Créteil, Sickle Cell Referral Center - UMGGR & IMRB, Laboratory of Excellence LABEX GRex, Créteil, FRANCE

K Ataga

2 UTHSC Center for Sickle Cell Disease, Memphis, TN, UNITED STATES

M Callaghan

3 Division of Pediatric Hematology/Oncology, Central Michigan University SOM, Children’s Hospital of Michigan, Detroit, MI, UNITED STATES

L De Franceschi

4 Department of Medicine, University of Verona and AOUI Verona, Verona, ITALY

C Minniti

5 Albert Einstein College of Medicine, Bronx, New York, NY, UNITED STATES

A Alexandrou

6 Roche Products Limited, Welwyn Garden City, UNITED KINGDOM

D Imbs

7 Certara, Inc., Paris, FRANCE

R Fox

8 Parexel International, Uxbridge, UNITED KINGDOM

H Patel

9 Genentech, Inc., South San Francisco, CA, UNITED STATES

A Sostelly

10 F. Hoffmann-La Roche Ltd, Basel, SWITZERLAND

J Schimmel

11 Icahn School of Medicine at Mount Sinai, Department of Emergency Medicine, New York. NY, UNITED STATES